Therapure Biopharma Report issue

For profit Phase 1 Phase 3
Founded: Mississauga ON Canada (2008)
Status: Acquired by 3SBio (2017) → now Shanghai CP Guojian Pharmaceutical Co.,Ltd. (2015)

Organization Overview

First Clinical Trial
2017
NCT03238079
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Therapure Biopharma | Therapure Biopharma Inc

Active Ingredients

Drugs in Phase 3 Trials (1)

immune globulin (human) (Gamastan) (1 trial)

Drugs in Phase 1 Trials (1)

tbi 302 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Deficiency Diseases (Phase 3)

Immunologic Deficiency Syndromes (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2